Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Evoke Pharma 5M share Spot Secondary priced at $2.50 » 20:07
01/13/21
01/13
20:07
01/13/21
20:07
EVOK

Evoke Pharma

$2.71 /

-0.03 (-1.09%)

Laidlaw acted as sole…

Laidlaw acted as sole book running manager for the offering.

ShowHide Related Items >><<
EVOK Evoke Pharma
$2.71 /

-0.03 (-1.09%)

EVOK Evoke Pharma
$2.71 /

-0.03 (-1.09%)

06/22/20 H.C. Wainwright
Evoke Pharma upgraded to Buy from Neutral at H.C. Wainwright
EVOK Evoke Pharma
$2.71 /

-0.03 (-1.09%)

  • 14
    Jan
Syndicate
Evoke Pharma 5M share Spot Secondary priced at $2.50 » 20:07
01/13/21
01/13
20:07
01/13/21
20:07
EVOK

Evoke Pharma

$2.71 /

-0.03 (-1.09%)

Laidlaw acted as sole…

Laidlaw acted as sole book running manager for the offering.

ShowHide Related Items >><<
EVOK Evoke Pharma
$2.71 /

-0.03 (-1.09%)

EVOK Evoke Pharma
$2.71 /

-0.03 (-1.09%)

06/22/20 H.C. Wainwright
Evoke Pharma upgraded to Buy from Neutral at H.C. Wainwright
EVOK Evoke Pharma
$2.71 /

-0.03 (-1.09%)

  • 14
    Jan
Syndicate
Evoke Pharma announces common stock offering, no amount given » 16:06
01/13/21
01/13
16:06
01/13/21
16:06
EVOK

Evoke Pharma

$2.77 /

+0.03 (+1.09%)

Evoke Pharma announced…

Evoke Pharma announced that it intends to offer and sell shares of its common stock in a "firm commitment" underwritten public offering. Evoke intends to use the net proceeds from the offering for working capital and general corporate purposes, including funding commercialization activities, research and development activities, clinical trial expenditures, and possible acquisition of new technologies or products. Laidlaw & Company is acting as sole book-running manager for the offering.

ShowHide Related Items >><<
EVOK Evoke Pharma
$2.77 /

+0.03 (+1.09%)

EVOK Evoke Pharma
$2.77 /

+0.03 (+1.09%)

06/22/20 H.C. Wainwright
Evoke Pharma upgraded to Buy from Neutral at H.C. Wainwright
EVOK Evoke Pharma
$2.77 /

+0.03 (+1.09%)

Hot Stocks
Evoke Pharma announces finding from GIMOTI market research study » 08:50
01/13/21
01/13
08:50
01/13/21
08:50
EVOK

Evoke Pharma

$2.74 /

+0.12 (+4.58%)

Evoke Pharma announced…

Evoke Pharma announced positive findings from the first market research for GIMOTI following its launch during the fourth quarter of 2020. During December 2020, Evoke through its marketing partner, EVERSANA, conducted an ATU Study, a quantitative survey to measure physician awareness, trial, and product usage, for GIMOTI. Approximately 104 total physician responses were captured. Survey respondents were split into three groups drawn from the healthcare practitioner community; "target" gastroenterologists currently being called on by the field sales force, other "non-target" gastroenterologists, and primary care physicians who are not currently targeted for messaging. Areas of interest that were queried included initial and future potential prescribing trends, and how HCPs viewed the suitability of GIMOTI in certain gastroparesis patient populations. Key Findings: Indicated an intent to prescribe GIMOTI: 79% of target gastroenterologists. 89% of non-target gastroenterologists. 50% of PCPs. Out of those target gastroenterologists indicating an intent to prescribe GIMOTI, 94% indicated GIMOTI would be "appropriate" to use in moderate to severe patients. A majority of each of the target and non-target gastroenterologists noted they intend to prescribe GIMOTI for both new and existing gastroparesis patients. Nineteen of all participating HCPs indicated that they have already written a prescription for GIMOTI. HCPs indicated that the primary driver for prescribing GIMOTI was patients being switched to GIMOTI due to lack of efficacy of current treatments.

ShowHide Related Items >><<
EVOK Evoke Pharma
$2.74 /

+0.12 (+4.58%)

EVOK Evoke Pharma
$2.74 /

+0.12 (+4.58%)

06/22/20 H.C. Wainwright
Evoke Pharma upgraded to Buy from Neutral at H.C. Wainwright
EVOK Evoke Pharma
$2.74 /

+0.12 (+4.58%)

Over a week ago
Syndicate
Evoke Pharma files $100M mixed securities shelf  17:30
12/22/20
12/22
17:30
12/22/20
17:30
EVOK

Evoke Pharma

$2.98 /

+0.1 (+3.47%)

 
ShowHide Related Items >><<
EVOK Evoke Pharma
$2.98 /

+0.1 (+3.47%)

EVOK Evoke Pharma
$2.98 /

+0.1 (+3.47%)

06/22/20 H.C. Wainwright
Evoke Pharma upgraded to Buy from Neutral at H.C. Wainwright
EVOK Evoke Pharma
$2.98 /

+0.1 (+3.47%)

EVOK Evoke Pharma
$2.98 /

+0.1 (+3.47%)

Over a month ago
Conference/Events
Evoke Pharma management to meet virtually with B. Riley Securities » 04:55
12/11/20
12/11
04:55
12/11/20
04:55
EVOK

Evoke Pharma

$2.89 /

-0.07 (-2.36%)

Virtual Meetings to be…

Virtual Meetings to be held December 9-11 hosted by B. Riley Securities.

ShowHide Related Items >><<
EVOK Evoke Pharma
$2.89 /

-0.07 (-2.36%)

EVOK Evoke Pharma
$2.89 /

-0.07 (-2.36%)

06/22/20 H.C. Wainwright
Evoke Pharma upgraded to Buy from Neutral at H.C. Wainwright
EVOK Evoke Pharma
$2.89 /

-0.07 (-2.36%)

EVOK Evoke Pharma
$2.89 /

-0.07 (-2.36%)

EVOK Evoke Pharma
$2.89 /

-0.07 (-2.36%)

Conference/Events
Evoke Pharma management to meet virtually with B. Riley Securities » 05:55
12/10/20
12/10
05:55
12/10/20
05:55
EVOK

Evoke Pharma

$2.96 /

-0.12 (-3.90%)

Virtual Meetings to be…

Virtual Meetings to be held December 9-11 hosted by B. Riley Securities.

ShowHide Related Items >><<
EVOK Evoke Pharma
$2.96 /

-0.12 (-3.90%)

EVOK Evoke Pharma
$2.96 /

-0.12 (-3.90%)

06/22/20 H.C. Wainwright
Evoke Pharma upgraded to Buy from Neutral at H.C. Wainwright
EVOK Evoke Pharma
$2.96 /

-0.12 (-3.90%)

EVOK Evoke Pharma
$2.96 /

-0.12 (-3.90%)

EVOK Evoke Pharma
$2.96 /

-0.12 (-3.90%)

Conference/Events
Evoke Pharma management to meet virtually with B. Riley Securities » 04:55
12/09/20
12/09
04:55
12/09/20
04:55
EVOK

Evoke Pharma

$3.08 /

-0.035 (-1.12%)

Virtual Meetings to be…

Virtual Meetings to be held December 9-11 hosted by B. Riley Securities.

ShowHide Related Items >><<
EVOK Evoke Pharma
$3.08 /

-0.035 (-1.12%)

EVOK Evoke Pharma
$3.08 /

-0.035 (-1.12%)

06/22/20 H.C. Wainwright
Evoke Pharma upgraded to Buy from Neutral at H.C. Wainwright
EVOK Evoke Pharma
$3.08 /

-0.035 (-1.12%)

EVOK Evoke Pharma
$3.08 /

-0.035 (-1.12%)

EVOK Evoke Pharma
$3.08 /

-0.035 (-1.12%)

Conference/Events
Evoke Pharma management to meet virtually with B. Riley Securities » 10:11
12/07/20
12/07
10:11
12/07/20
10:11
EVOK

Evoke Pharma

$3.07 /

+ (+0.00%)

Virtual Meetings to be…

Virtual Meetings to be held December 9-11 hosted by B. Riley Securities.

ShowHide Related Items >><<
EVOK Evoke Pharma
$3.07 /

+ (+0.00%)

EVOK Evoke Pharma
$3.07 /

+ (+0.00%)

06/22/20 H.C. Wainwright
Evoke Pharma upgraded to Buy from Neutral at H.C. Wainwright
EVOK Evoke Pharma
$3.07 /

+ (+0.00%)

EVOK Evoke Pharma
$3.07 /

+ (+0.00%)

EVOK Evoke Pharma
$3.07 /

+ (+0.00%)

Earnings
Evoke Pharma reports Q3 EPS (8c), consensus (8c) » 08:34
11/10/20
11/10
08:34
11/10/20
08:34
EVOK

Evoke Pharma

$3.39 /

-0.35 (-9.36%)

Research and development…

Research and development expenses totaled approximately $0.2 million for the third quarter of 2020, compared to approximately $0.8 million for the third quarter of 2019. The decrease during the three months ended September 30, 2020 was primarily due to the decrease in research and development activity following the GIMOTI NDA approval in June 2020. As of September 30, 2020, the Company's cash and cash equivalents were approximately $6.3 million. The Company expects that its current cash balance will be sufficient to support operations into the second quarter of 2021, without consideration of potential future GIMOTI revenue.

ShowHide Related Items >><<
EVOK Evoke Pharma
$3.39 /

-0.35 (-9.36%)

EVOK Evoke Pharma
$3.39 /

-0.35 (-9.36%)

06/22/20 H.C. Wainwright
Evoke Pharma upgraded to Buy from Neutral at H.C. Wainwright
EVOK Evoke Pharma
$3.39 /

-0.35 (-9.36%)

EVOK Evoke Pharma
$3.39 /

-0.35 (-9.36%)

EVOK Evoke Pharma
$3.39 /

-0.35 (-9.36%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.